Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

October 23, 2019

Study Completion Date

October 23, 2019

Conditions
Type 1 Diabetes
Interventions
DEVICE

Tandem t:slim X2 with Control-IQ Technology + Dexcom G6

Subjects will use the Tandem t:slim X2 with Control- IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].

Trial Locations (3)

22903

University of Virginia Center for Diabetes Technology, Charlottesville

80045

Barbara Davis Center, University of Colorado, Aurora

94304

Stanford University, Stanford

All Listed Sponsors
collaborator

DexCom, Inc.

INDUSTRY

collaborator

Tandem Diabetes Care, Inc.

INDUSTRY

lead

University of Virginia

OTHER

NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 | Biotech Hunter | Biotech Hunter